Related Experiment Videos
PIF* promotes brain re-myelination locally while regulating systemic inflammation- clinically relevant multiple
Giuseppe Migliara1,2, Martin Mueller3,4, Alessia Piermattei1
1Università Cattolica del S. Cuore, Institute of General Pathology, Largo Francesco Vito, 100168 Rome, Italy.
Oncotarget
|April 21, 2017
Summary
PreImplantation Factor (PIF) shows promise for treating Multiple Sclerosis (MS) by promoting brain re-myelination and reversing paralysis in a key animal model. This immune-modulating peptide offers neuroprotection and supports potential therapies for neurodegenerative disorders.
Area of Science:
- Neuroimmunology
- Neurodegenerative Diseases
- Drug Discovery
Background:
- Multiple Sclerosis (MS) is a debilitating autoimmune disease affecting the central nervous system (CNS) with complex etiology.
- Current therapeutic strategies for MS are limited, necessitating novel approaches.
- PreImplantation Factor (PIF), an embryonic peptide, exhibits immunomodulatory properties and has shown protective effects in preclinical models.
Purpose of the Study:
- To investigate the therapeutic potential of synthetic PIF in a relapsing-remitting experimental autoimmune encephalitis (EAE) model of MS.
- To elucidate the mechanisms by which PIF exerts neuroprotective and remyelinating effects in the CNS.
Main Methods:
- Administration of synthetic PIF to EAE mice.
- Assessment of clinical outcomes, including paralysis reversal and motor function.
- Analysis of blood-brain barrier penetration and immune cell targeting (microglia).
- Measurement of cytokine profiles (IL23, IL17, IL10, IFNγ) and T-cell repertoire.
- Global brain gene expression analysis and targeted gene expression in astrocytes and microglia.
Main Results:
- PIF treatment reversed paralysis and promoted significant brain re-myelination in the EAE MS model.
- PIF effectively crossed the blood-brain barrier and targeted microglia.
- Systemic administration of PIF reduced pro-inflammatory cytokines (IL23, IL17) while preserving the CNS-specific T-cell repertoire.
- PIF modulated key genes involved in ion transport, glucose metabolism, oxidative stress, and DNA methylation.
- In vitro studies showed PIF promoted myelin synthesis and neurotrophic factors in astrocytes and reduced pro-inflammatory mediators in microglia.
Conclusions:
- Synthetic PIF demonstrates significant therapeutic potential for MS by promoting re-myelination and neuroprotection.
- PIF's mechanism involves modulation of immune responses, gene expression, and cellular processes within the CNS.
- These findings support the further clinical investigation of PIF for neurodegenerative disorders, with an ongoing FDA-approved clinical trial.